Home Healthcare Medical Devices North America Cardiac Resynchronization Therapy (CRT) Market

North America Cardiac Resynchronization Therapy (CRT) Market Size, Share & Trends Analysis Report By Product (CRT-Defibrillator, CRT-Pacemaker), By End User (Hospitals, Cardiac Centers, Ambulatory Surgical Centers, Other End Users) and By Country (U.S., Canada) Forecasts, 2026-2034

Last Updated: September 21, 2026 | Author: Debashree Bora | Format:

Market Overview

The North America Cardiac Resynchronization Therapy (CRT) Market size was valued at USD 2.11 billion in 2025 and is projected to grow from USD 2.22 billion in 2026 to reach USD 3.31 billion by 2034, growing at a CAGR of 5.12% during the forecast period 2026–2034.

Cardiac resynchronization therapy (CRT) is a treatment that assists the heart in beating at the correct rate. It employs a pacemaker to restore the heartbeat's normal timing pattern. The CRT pacemaker coordinates the synchronization of the heart's upper (atria) and lower (ventricles) chambers. It also regulates the synchronization between the heart's left and right sides.

The market for cardiac resynchronization therapy (CRT) was estimated to be worth USD 5.85 billion in 2021. One of the major trends accelerating market expansion is the rapid advancement of technology. The market is expanding due to sedentary lifestyle adoption, an aging population, and increased cardiovascular disease prevalence.

The CRT-D segment had the biggest market share because of high demand, accounting for 58.3% of all products in 2021. The CRT-P segment's fastest growth rate is anticipated due to numerous technological developments. The top competitors on the market include Medtronic, Abbott, Boston Scientific Corporation, BIOTRONIK, and MicroPort Scientific Corporation.

Market Key Takeaways

Global Market Size & Growth

CRT-D dominates the market by Product.
Hospitals dominate the market by End-User.
U.S. dominates the market by Country.
North America Cardiac Resynchronization Therapy (CRT) Market Size

Download a Free Sample To learn more about this report.

North America Cardiac Resynchronization Therapy (CRT) Market Segmentation Analysis

By Product

The North America Cardiac Resynchronization Therapy (CRT) Market is segmented into CRT-Defibrillator and CRT-Pacemaker. CRT-Defibrillators combine cardiac resynchronization capabilities with implantable cardioverter-defibrillator functionality, allowing them to support heart rhythm synchronization while also providing protection against potentially life-threatening ventricular arrhythmias. CRT-Pacemakers are designed primarily to coordinate ventricular contractions and improve cardiac synchronization in eligible patients with heart failure and conduction abnormalities. Both product categories are widely used in cardiovascular care, with product selection depending on patient condition, arrhythmia risk, clinical guidelines, and physician assessment.

Increasing prevalence of heart failure, growing aging populations, rising diagnosis of cardiac rhythm disorders, and technological advancements in implantable cardiac devices are supporting demand across both product categories. CRT-Pacemakers represented a major product segment in North America, while CRT-Defibrillators continue to benefit from their ability to provide both resynchronization and defibrillation functions. Improvements in device miniaturization, battery life, remote monitoring, lead technology, and implantation techniques are expected to strengthen adoption of advanced CRT systems across the region.

North America Cardiac Resynchronization Therapy (CRT) Market Size By Segments

Request Customizationto receive a tailored report.

By End User

The North America Cardiac Resynchronization Therapy (CRT) Market is segmented into Hospitals, Cardiac Centers, Ambulatory Surgical Centers, and Other End Users. Hospitals represent a major end-user segment because CRT implantation and related cardiac procedures require specialized infrastructure, cardiovascular specialists, diagnostic capabilities, and post-procedure monitoring. Cardiac centers provide specialized cardiovascular diagnosis, treatment, device implantation, and follow-up care, while ambulatory surgical centers are increasingly relevant for selected procedures that can be performed in outpatient settings. Other end users include specialized healthcare facilities and medical institutions involved in cardiac rhythm management and patient monitoring.

Growing demand for advanced cardiovascular care, increasing prevalence of heart failure and cardiac rhythm disorders, expansion of specialized cardiac facilities, and improvements in minimally invasive implantation techniques are supporting demand across end-user settings. Hospitals continue to benefit from their comprehensive cardiac-care infrastructure, while cardiac centers are gaining importance because of their specialized expertise and increasing focus on advanced rhythm-management procedures. Ambulatory surgical centers can benefit from the expansion of outpatient cardiovascular interventions, while remote monitoring and improved follow-up technologies are enhancing long-term management of CRT patients across North America.

North America Cardiac Resynchronization Therapy (CRT) Market Share By Segments

Speak to an Analystto discuss market opportunities.

Regional Analysis

The North American cardiac resynchronization therapy market is segmented by country into U.S. and Canada. U.S. dominates the country market and is expected to grow at a CAGR of 6.8% during the forecast period.

Due to its growing geriatric population and regulatory clearances, North America is anticipated to dominate the CRT market throughout the forecast period. The risk of developing chronic heart diseases might rise due to sedentary lifestyles, which may increase the requirement for cardiovascular care. Additionally, several medical gadget suppliers in this area offer cardiovascular care internationally. These businesses are concentrating on releasing cutting-edge products with attributes like enhanced battery life and miniaturization, which are predicted to fuel market expansion.

List of Key and Emerging Players in North America Cardiac Resynchronization Therapy (CRT) Market

Abbott
Boston Scientific Corporation
Medtronic
Biotronik SE & Co. Kg
Microport Scientific Corporation
LivaNova PLC
Medico S.R.L.

Key Industry Developments

April 2026
Abbott launched upgraded Gallant™ CRT devices featuring improved arrhythmia detection, MRI compatibility, and enhanced remote patient monitoring capabilities for cardiac care providers.
February 2026
Boston Scientific expanded its cardiac rhythm management portfolio with next-generation CRT systems offering AI-assisted diagnostics and optimized pacing technologies for personalized heart failure treatment.
October 2025
BIOTRONIK introduced advanced CRT-P and CRT-D devices with enhanced physiological pacing capabilities and expanded digital connectivity for long-term patient management.
August 2025
MicroPort CRM strengthened its North American cardiac rhythm portfolio by expanding access to innovative CRT technologies through strategic clinical collaborations and physician training initiatives.

Report Scope

Segmentation

By Product 2
  • CRT-Defibrillator
  • CRT-Pacemaker
By End User 4
  • Hospitals
  • Cardiac Centers
  • Ambulatory Surgical Centers
  • Other End Users
Competitive Coverage Abbott · Boston Scientific Corporation · Medtronic · Biotronik SE & Co. Kg · Microport Scientific Corporation
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The North American cardiac resynchronization therapy size is growing at a CAGR of 5.12% from 2026 to 2034.

Increasing prevalence of cardiovascular diseases is the key driver for the growth of the optical transport network market.

The growing cases of cardiovascular diseases is one of the upcoming trend in the optical transport network market.

The key players in the North American cardiac resynchronization therapy include Nokia Corporation, Ciena Corporation, Cisco Systems Inc., Huawei Technologies Co. Ltd, ZTE Corporation, Fujitsu Ltd, Infinera Corporation, Telefonaktiebolaget LM Ericsson, NEC Corporation, Yokogawa Electric Corporation.
About the Author
Debashree Bora
Debashree Bora
Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.

Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Request Sample Order Report Now

We are featured on: